UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 24, 2017
ENTEST BIOMEDICAL, INC.
(Exact Name of Company as Specified in Charter)
| | | |
| | | |
| Nevada | 333-154989 | 26-3431263 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
| |
| 4700 Spring Street, Suite 304 |
| La Mesa California, 91942 |
| (Address of Principal Executive Offices, Zip Code) |
| |
| 619-702-1404 |
| (Company’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On October 24, 2017 Zander Therapeutics, Inc. (a subsidiary of Entest BioMedical, Inc. under common control with Entest BioMedical, Inc.) issued an aggregate of 900,000 of its common shares (“Shares”) to three trusts under common control for aggregate consideration of $900,000.
The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares. The proceeds from the sale of the Shares were utilized for general corporate purposes.
Item 9.01. Financial Statements and Exhibits.
EXHIBIT INDEX
10.1 Form of Agreements for sale of Shares.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENTEST BIOMEDICAL, INC | | |
| | | |
| By: | /s/ David R. Koos | | |
| | David R. Koos | | |
| | Chief Executive Officer | | |
| Dated: | October 25, 2017 | | |
